During a lead-in period , patients received twice daily ( b.i.d. ) axitinib 7 mg ( n = 3 ) or 10 mg ( n = 18 ) for 7 days followed by a 7-day dosing interruption ; serial ( 18 ) FLT-PET scans were performed before day 1 and on days 7 , 10 , and 14 .